Maharashtra’s proposed expansion of rare-disease treatment under the Mahatma Jyotiba Phule Jan Arogya Yojana (MJPJAY) could link financial assistance more closely with diagnosis, hospital registration, medicine procurement and treatment for patients with spinal muscular atrophy (SMA), according to a Free Press Journal report.
Deputy Chief Minister Eknath Shinde issued the directions during a review meeting on rare diseases at Vidhan Bhavan in Mumbai on Wednesday. The meeting was attended by senior Health Department officials, paediatric specialists from Wadia and KEM hospitals, and representatives of the Jija social organisation, the report said.
The Health Department has been asked to prepare an SOP for SMA covering early diagnosis, patient registration, treatment procedures and the availability of oral medicines. The stated objective is to prevent financial constraints from forcing patients to discontinue treatment.
The report said KEM Hospital has been designated as a Centre of Excellence for rare diseases in Maharashtra and handles diagnosis, registration and treatment-related procedures. Shinde called for a clearly defined treatment protocol to improve the coordination of these services.
He also directed KEM to add essential medicines for rare diseases to its essential medicines list and begin procurement. The direction is intended to support uninterrupted availability for patients receiving treatment through the facility, although the report does not provide procurement quantities, costs or an implementation schedule.
The meeting also reviewed the status of SMA patients in Maharashtra, early diagnosis, available treatment options, medicine availability and difficulties faced by patients and their families. The report does not state how many patients would be covered if rare-disease treatment is included under MJPJAY, or when the proposed coverage and SOP would take effect.
Separately, officials were asked to submit a proposal to the Union Health Ministry seeking Centre of Excellence status for Mumbai’s Wadia Children’s Hospital, which the report said already provides treatment facilities for SMA patients. Shinde was also reported to have said that he would write to the Union Health Minister to pursue the proposal.
The measures place public hospitals at the centre of a proposed care pathway for rare diseases: early identification, specialist treatment, access to medicines and financial support. Their practical effect will depend on the final MJPJAY coverage rules, the SOP, medicine procurement and any decision on Wadia’s Centre of Excellence proposal.


